NCT04274452View on ClinicalTrials.gov

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 29, 2020

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
BIOLOGICAL

efgartigimod

Intravenous infusion of efgartigimod

OTHER

Placebo

Intravenous infusion of placebo

Sponsors

Lead Sponsor

argenx
All Listed Sponsors
lead

argenx

INDUSTRY